These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6213319)

  • 1. Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology.
    Tamassia V; Battaglia A; Ganzina F; Isetta AM; Sacchetti G; Cavalli F; Goldhirsch A; Brunner K; Bernardo G; Robustelli della Cuna G
    Cancer Chemother Pharmacol; 1982; 8(2):151-6. PubMed ID: 6213319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
    Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
    Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.
    Camaggi CM; Strocchi E; Giovannini M; Angelelli B; Costanti B; Zebini E; Ferrari P; Pannuti F
    Cancer Chemother Pharmacol; 1983; 11(1):19-22. PubMed ID: 6224604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer.
    Camaggi CM; Strocchi E; Costanti B; Beghelli P; Ferrari P; Pannuti F
    Cancer Chemother Pharmacol; 1985; 14(3):232-4. PubMed ID: 3158449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
    Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
    J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
    Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
    Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
    Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
    Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MPA at high doses in advanced breast cancer: a statistical evaluation.
    Pannuti F; Camaggi CM; Strocchi E; Martoni A
    Chemioterapia; 1986 Jun; 5(3):159-63. PubMed ID: 2941172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.
    Salimtschik M; Mouridsen HT; Loeber J; Johansson E
    Cancer Chemother Pharmacol; 1980; 4(4):267-9. PubMed ID: 7438329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
    Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
    Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma.
    Laatikainen T; Nieminen U; Adlercreutz H
    Acta Obstet Gynecol Scand; 1979; 58(1):95-9. PubMed ID: 419965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
    Canney PA; Dowsett M; Priestman TJ
    Br J Cancer; 1988 Jul; 58(1):73-6. PubMed ID: 2971386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medroxyprogesterone acetate (MAP) plasma levels after simultaneous oral and intramuscular administration in cancer patients.
    Pannuti F; Camaggi CM; Strocchi E; Giovannini M; Canova N; Murari G
    Cancer Chemother Pharmacol; 1982; 9(2):122-3. PubMed ID: 6216987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
    Stockdale AD; Chapman D; Mould GP; Rostom AY
    Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of injection volume on the bioavailability of sterile medroxyprogesterone acetate suspension.
    Wright CE; Antal EJ; Gillespie WR; Albert KS
    Clin Pharm; 1983; 2(5):435-8. PubMed ID: 6226473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
    Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
    Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.
    Blossey HC; Bartsch HH; Kanne D; Koebberling J; Nagel GA
    Cancer Chemother Pharmacol; 1982; 8(1):77-81. PubMed ID: 6212156
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic study of different doses of Depo Provera.
    Fotherby K; Koetsawang S; Mathrubutham M
    Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation.
    Johansson ED; Johansen PB; Rasmussen SN
    Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):311-7. PubMed ID: 2943134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.